BACKGROUND: Extracorporeal shockwave therapy has been shown to be effective in the treatment of chronic tendon pathology in the elbow, shoulder, and plantar fascia. This prospective study examines the efficacy of extracorporeal shockwave therapy in the treatment of chronic Achilles tendon disorders. METHODS: Twenty-three patients (23 feet) were treated with extracorporeal shockwave therapy for Achilles tendinosis, insertional tendonitis, or both. Indications for treatment were a minimum of 6 months of conservative care, and a visual analog pain score >5. The mean follow-up was 20 months (range, 4-35 months). RESULTS: Ninety-one percent (14 patients) were satisfied or very satisfied (23 patients) with treatment. Eighty-seven percent (20 patients) stated that extracorporeal shockwave therapy improved their condition, 13% (3 patients) said it did not affect the condition, and none stated that it made them worse. Eighty-seven percent (20 patients) stated they would have the procedure again if given the choice. Four months after extracorporeal shockwave therapy, the mean visual analog score for morning pain decreased from 7.0 to 2.3, and activity pain decreased from 8.1 to 3.1. CONCLUSION: High-power extracorporeal shockwave therapy is safe, noninvasive, and effective, and it has a role in the treatment of chronic Achilles tendinopathy.
BACKGROUND: Extracorporeal shockwave therapy has been shown to be effective in the treatment of chronic tendon pathology in the elbow, shoulder, and plantar fascia. This prospective study examines the efficacy of extracorporeal shockwave therapy in the treatment of chronic Achilles tendon disorders. METHODS: Twenty-three patients (23 feet) were treated with extracorporeal shockwave therapy for Achilles tendinosis, insertional tendonitis, or both. Indications for treatment were a minimum of 6 months of conservative care, and a visual analog pain score >5. The mean follow-up was 20 months (range, 4-35 months). RESULTS: Ninety-one percent (14 patients) were satisfied or very satisfied (23 patients) with treatment. Eighty-seven percent (20 patients) stated that extracorporeal shockwave therapy improved their condition, 13% (3 patients) said it did not affect the condition, and none stated that it made them worse. Eighty-seven percent (20 patients) stated they would have the procedure again if given the choice. Four months after extracorporeal shockwave therapy, the mean visual analog score for morning pain decreased from 7.0 to 2.3, and activity pain decreased from 8.1 to 3.1. CONCLUSION: High-power extracorporeal shockwave therapy is safe, noninvasive, and effective, and it has a role in the treatment of chronic Achilles tendinopathy.
Authors: Nevin T Wijesekera; Ne Siang Chew; Justin C Lee; Adam W Mitchell; James D Calder; Jeremiah C Healy Journal: Skeletal Radiol Date: 2010-02-01 Impact factor: 2.199
Authors: Karin Grävare Silbernagel; Peter Malliaras; Robert-Jan de Vos; Shawn Hanlon; Mitchel Molenaar; Håkan Alfredson; Inge van den Akker-Scheek; Jarrod Antflick; Mathijs van Ark; Kenneth Färnqvist; Zubair Haleem; Jean-Francois Kaux; Paul Kirwan; Bhavesh Kumar; Trevor Lewis; Adrian Mallows; Lorenzo Masci; Dylan Morrissey; Myles Murphy; Richard Newsham-West; Richard Norris; Seth O'Neill; Koen Peers; Igor Sancho; Kayla Seymore; Patrick Vallance; Arco van der Vlist; Bill Vicenzino Journal: Sports Med Date: 2021-11-19 Impact factor: 11.136